| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $2,885,242 ) |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289387 | Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence. | 000 | 2 | NIH | 12/10/2025 | $591,410 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01ES035723 | H3 histone oxidation is a new posttranslational modification linking heavy metal-induced metabolic changes and oncegenic epigenetic reprogramming | 001 | 4 | NIH | 12/8/2025 | $444,350 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289581 | Release of interleukin-1a as a mediator of immune evasion in cancer | 000 | 2 | NIH | 12/9/2025 | $511,684 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 3 | NIH | 12/11/2025 | $559,022 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 4 | NIH | 12/9/2025 | $480,943 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 000 | 15 | NIH | 12/17/2025 | $304,497 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286417 | Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA230042 | Investigation of NRF2-Dependent Metabolic Liabilities | 000 | 7 | NIH | 11/19/2025 | -$3,210 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA222215 | Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy | 000 | 7 | NIH | 12/9/2025 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286226 | L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | 000 | 1 | NIH | 11/19/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA233399 | Integrated Program in Cancer and Data Science | 000 | 5 | NIH | 12/2/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21ES035196 | Novel role of melanin-carbonyls in progression of NRAS mutant melanoma | 000 | 1 | NIH | 11/21/2025 | -$437 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21AR081633 | Exploratory Study of T Cell Skin Trafficking and the Role of NKG2D Signaling; Implications in Vitiligo and Melanoma | 000 | 1 | NIH | 12/11/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA278603 | Health-related quality of life and patient reported outcomes among people living with HIV and cancer | 000 | 1 | NIH | 11/24/2025 | -$2 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241559 | Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250018 | Functional characterization of prostate cancer risk loci by high throughput sequencing | 000 | 4 | NIH | 11/25/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA236034 | A Stepped-care Psychosocial Intervention for Brain Tumor Family Caregivers | 000 | 5 | NIH | 11/24/2025 | -$3,015 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | CE152143 | Community Project Funding/Congressionally Directed Spending - Construction | 05 | 1 | HRSA | 12/4/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $53,797,384 ) (Continued on the next page) |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 000 | 2 | NIH | 5/12/2025 | $553,041 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 000 | 2 | NIH | 6/26/2025 | $485,494 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R00CA270423 | Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC | 000 | 4 | NIH | 8/19/2025 | $248,578 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 002 | 4 | NIH | 9/23/2025 | $141,464 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 001 | 4 | NIH | 9/22/2025 | $146,655 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 000 | 4 | NIH | 9/19/2025 | $337,724 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA273034 | Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors | 001 | 4 | NIH | 9/1/2025 | $770,888 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 000 | 5 | NIH | 3/21/2025 | $370,575 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 001 | 5 | NIH | 8/8/2025 | $41,175 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL163820 | A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury | 001 | 4 | NIH | 7/23/2025 | $613,814 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA266803 | An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy | 000 | 4 | NIH | 9/8/2025 | $1,345,854 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DA055298 | Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | 000 | 4 | NIH | 5/16/2025 | $759,650 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 4 | NIH | 6/25/2025 | $485,968 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA268973 | HIV Genomic Aging Project in Oncology (HIV-GAP) | 000 | 5 | NIH | 8/28/2025 | $763,464 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA256193 | Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | 000 | 5 | NIH | 8/11/2025 | $651,147 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255398 | Characterizing oncogenic function of ITCH in melanoma | 000 | 5 | NIH | 7/1/2025 | $357,913 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA244328 | Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | 000 | 4 | NIH | 8/20/2025 | $770,748 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249016 | Radiomics and Pathomics to predict upstaging of DCIS | 001 | 5 | NIH | 5/22/2025 | $68,269 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249016 | Radiomics and Pathomics to predict upstaging of DCIS | 000 | 5 | NIH | 4/25/2025 | $614,438 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM142577 | New reagents for C-C and C-N bond formation | 000 | 5 | NIH | 4/16/2025 | $411,750 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262121 | Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds | 000 | 5 | NIH | 7/16/2025 | $376,751 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P01CA250984 | Identifying Metabolic Vulnerabilities in Lung Cancer | 000 | 5 | NIH | 6/25/2025 | $2,032,950 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 001 | 5 | NIH | 5/22/2025 | $44,459 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 5 | NIH | 2/13/2025 | $400,132 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 001 | 5 | NIH | 5/22/2025 | $47,602 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 5 | NIH | 3/13/2025 | $428,435 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA252042 | Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | 001 | 5 | NIH | 9/12/2025 | $663,923 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 001 | 6 | NIH | 5/1/2025 | $498,468 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 000 | 5 | NIH | 6/26/2025 | $681,912 |
|
